Deals and Financings
I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million (see story). The company plans to offer 7.4 million shares at a price that ranges from $12 to $15. Final pricing is expected on January 16. In addition, I-Mab has dosed the first patient in a registrational China Phase II trial of a CD38 antibody in patients with relapsed-refractory multiple myeloma ((MM)). In 2017, I-Mab in-licensed greater China rights to the antibody from Germany's MorphoSys